Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation
AssigneeProtab Ltd.
InventorsYaakov Naparstek, Eli Moallem
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
Claims20
A composition for the modulation of the Th1/Th2 balance in a subject in need thereof comprising as an active ingredient an immuno-modulatory effective amount of at least one of:
- a. a compound that interacts with Adenylyl Cyclase-Associated Protein (CAP1);
- and
- b. CAP1 or any fragment, variant, derivative, homologue and mutant thereof;
- or any combination thereof, said composition optionally further comprises a pharmaceutically acceptable carrier, excipient or diluent.
A method for treating, preventing, ameliorating or delaying the onset of an immune-related disorder in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of at least one of:
- a. a compound that interacts with Adenylyl Cyclase-Associated Protein (CAP1);
- and
- b. CAP1 or any fragment, variant, derivative, homologue and mutant thereof;
- or any combination thereof or any composition comprising the same.
Use of a therapeutically effective amount of at least one of:
- a. a compound that interacts with Adenylyl Cyclase-Associated Protein (CAP1);
- and
- b. CAP1 or any fragment, variant, derivative, homologue and mutant thereof, or any combination thereof, in the preparation of a composition for treating, preventing, ameliorating or delaying the onset of an immune-related disorder, in a subject in need thereof.
Adenylyl Cyclase-Associated Protein (CAP1) or any fragment, variant, derivative, homologue and mutant thereof, that modulates the balance between Th1/Th2 in a subject in need thereof, for use in treating, preventing, ameliorating or delaying the onset of an immune-related disorder in said subject.
An anti-CAP1 antibody that specifically recognizes and binds CAP1, thereby modulating the balance between Th1/Th2 towards the Th2 anti-inflammatory response in a subject in need thereof, for use in treating, preventing, ameliorating or delaying the onset of an immune-related disorder in said subject.
A screening method for an immuno-modulating compound which modulates the Th1/Th2 cell balance in a subject in need thereof, which method comprises the steps of:
- a. obtaining a candidate compound which binds to CAP1 or to any fragment, variant, derivative, homologue and mutant thereof;
- b. determining the effect of the compound selected in step (a), on modulation of an anti-inflammatory or pro-inflammatory cytokine expression.
- whereby modulation of an anti-inflammatory or a pro-inflammatory cytokine expression by said candidate compound is indicative of the ability of said compound to modulate the Th1/Th2 balance in said subject.
A pharmaceutical unit dosage form comprising as an active ingredient a therapeutically effective amount of at least one of:
- a. a compound that interacts with Adenylyl Cyclase-Associated Protein (CAP1);
- and
- b. CAP1 or any fragment, variant, derivative, homologue and mutant thereof;
- or any combination thereof,
- for the preparation of a medicament effective in treating, preventing, ameliorating or delaying the onset of an immune-related disorder, said dosage form optionally further comprises a pharmaceutically acceptable carrier, excipient or diluent.
Dependencies are inferred from the claim text.